Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| REGENERON PHARMACEUTICALS, INC.REGN · Entity 2010 | EVP Research and Development | December 16, 2024 | December 18, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
REGENERON PHARMACEUTICALS, INC.
Report date December 16, 2024 · Filed December 18, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 48,829 |
Reported balance
After 2024-12-16 transaction · row 1
1 source rowRow 1 · 2024-12-16 · Tax withholding · Disposed 304 · Balance 48,829 |
| Common StockSEC Table I · non-derivative | IndirectBy 401(k) Plan | 5,849 |
Reported balance
Holding disclosure · report date 2024-12-16 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 5,849 |
| Common StockSEC Table I · non-derivative | Indirectby Spouse as Trustee | 4,605 |
Reported balance
Holding disclosure · report date 2024-12-16 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 4,605 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 27, 2020 Filed Feb 28, 2020 21:40 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1 | $462.15 | $462.15 |
DisclosureSEC source: 0001708138-20-000017 · edgardoc.xml · nonDerivative · entry 26 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,887 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| February 27, 2020 Filed Feb 28, 2020 21:40 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 614 | $461.24 | $283,201.36 |
DisclosureSEC source: 0001708138-20-000017 · edgardoc.xml · nonDerivative · entry 25 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,888 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F21 · price: Represents volume-weighted average price of sales of 614 shares of Company stock on February 27, 2020 at prices ranging from $461.00 to $461.81. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 27, 2020 at each separate price. Read SEC document |
| February 27, 2020 Filed Feb 28, 2020 21:40 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 252 | $460.34 | $116,005.68 |
DisclosureSEC source: 0001708138-20-000017 · edgardoc.xml · nonDerivative · entry 24 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,502 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F20 · price: Represents volume-weighted average price of sales of 252 shares of Company stock on February 27, 2020 at prices ranging from $460.02 to $460.70. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 27, 2020 at each separate price. Read SEC document |
| February 27, 2020 Filed Feb 28, 2020 21:40 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 692 | $459.47 | $317,953.24 |
DisclosureSEC source: 0001708138-20-000017 · edgardoc.xml · nonDerivative · entry 23 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,754 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F19 · price: Represents volume-weighted average price of sales of 692 shares of Company stock on February 27, 2020 at prices ranging from $459.09 to $459.90. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 27, 2020 at each separate price. Read SEC document |
| February 27, 2020 Filed Feb 28, 2020 21:40 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 460 | $458.59 | $210,951.40 |
DisclosureSEC source: 0001708138-20-000017 · edgardoc.xml · nonDerivative · entry 22 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,446 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F18 · price: Represents volume-weighted average price of sales of 460 shares of Company stock on February 27, 2020 at prices ranging from $458.31 to $458.90. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 27, 2020 at each separate price. Read SEC document |
| February 27, 2020 Filed Feb 28, 2020 21:40 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 141 | $457.27 | $64,475.07 |
DisclosureSEC source: 0001708138-20-000017 · edgardoc.xml · nonDerivative · entry 21 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,906 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F17 · price: Represents volume-weighted average price of sales of 141 shares of Company stock on February 27, 2020 at prices ranging from $457.11 to $457.64. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 27, 2020 at each separate price. Read SEC document |
| February 27, 2020 Filed Feb 28, 2020 21:40 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 743 | $456.63 | $339,276.09 |
DisclosureSEC source: 0001708138-20-000017 · edgardoc.xml · nonDerivative · entry 20 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,047 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F16 · price: Represents volume-weighted average price of sales of 743 shares of Company stock on February 27, 2020 at prices ranging from $456.10 to $456.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 27, 2020 at each separate price. Read SEC document |
| February 27, 2020 Filed Feb 28, 2020 21:40 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2,967 | $455.56 | $1,351,646.52 |
DisclosureSEC source: 0001708138-20-000017 · edgardoc.xml · nonDerivative · entry 19 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,790 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F15 · price: Represents volume-weighted average price of sales of 2,967 shares of Company stock on February 27, 2020 at prices ranging from $455.11 to $455.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 27, 2020 at each separate price. Read SEC document |
| February 27, 2020 Filed Feb 28, 2020 21:40 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 102 | $454.58 | $46,367.16 |
DisclosureSEC source: 0001708138-20-000017 · edgardoc.xml · nonDerivative · entry 18 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,757 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F14 · price: Represents volume-weighted average price of sales of 102 shares of Company stock on February 27, 2020 at prices ranging from $454.58 to $454.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 27, 2020 at each separate price. Read SEC document |
| February 27, 2020 Filed Feb 28, 2020 21:40 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 113 | $453.45 | $51,239.85 |
DisclosureSEC source: 0001708138-20-000017 · edgardoc.xml · nonDerivative · entry 17 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,859 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| February 27, 2020 Filed Feb 28, 2020 21:40 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 130 | $452.08 | $58,770.40 |
DisclosureSEC source: 0001708138-20-000017 · edgardoc.xml · nonDerivative · entry 16 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,972 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| February 27, 2020 Filed Feb 28, 2020 21:40 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 233 | $451.47 | $105,192.51 |
DisclosureSEC source: 0001708138-20-000017 · edgardoc.xml · nonDerivative · entry 15 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,102 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F13 · price: Represents volume-weighted average price of sales of 233 shares of Company stock on February 27, 2020 at prices ranging from $451.07 to $451.83. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 27, 2020 at each separate price. Read SEC document |
| February 27, 2020 Filed Feb 28, 2020 21:40 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 125 | $450.10 | $56,262.50 |
DisclosureSEC source: 0001708138-20-000017 · edgardoc.xml · nonDerivative · entry 14 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,335 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| February 27, 2020 Filed Feb 28, 2020 21:40 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 236 | $449.53 | $106,089.08 |
DisclosureSEC source: 0001708138-20-000017 · edgardoc.xml · nonDerivative · entry 13 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,460 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F12 · price: Represents volume-weighted average price of sales of 236 shares of Company stock on February 27, 2020 at prices ranging from $449.25 to $449.87. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 27, 2020 at each separate price. Read SEC document |
| February 27, 2020 Filed Feb 28, 2020 21:40 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 240 | $448.86 | $107,726.40 |
DisclosureSEC source: 0001708138-20-000017 · edgardoc.xml · nonDerivative · entry 12 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,696 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F11 · price: Represents volume-weighted average price of sales of 240 shares of Company stock on February 27, 2020 at prices ranging from $448.73 to $448.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 27, 2020 at each separate price. Read SEC document |
| February 27, 2020 Filed Feb 28, 2020 21:40 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 120 | $445.91 | $53,509.20 |
DisclosureSEC source: 0001708138-20-000017 · edgardoc.xml · nonDerivative · entry 11 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,936 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F10 · price: Represents volume-weighted average price of sales of 120 shares of Company stock on February 27, 2020 at prices ranging from $445.91 to $445.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 27, 2020 at each separate price. Read SEC document |
| February 27, 2020 Filed Feb 28, 2020 21:40 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 490 | $444.65 | $217,878.50 |
DisclosureSEC source: 0001708138-20-000017 · edgardoc.xml · nonDerivative · entry 10 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,056 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F9 · price: Represents volume-weighted average price of sales of 490 shares of Company stock on February 27, 2020 at prices ranging from $444.35 to $444.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 27, 2020 at each separate price. Read SEC document |
| February 27, 2020 Filed Feb 28, 2020 21:40 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 264 | $443.67 | $117,128.88 |
DisclosureSEC source: 0001708138-20-000017 · edgardoc.xml · nonDerivative · entry 9 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,546 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F8 · price: Represents volume-weighted average price of sales of 264 shares of Company stock on February 27, 2020 at prices ranging from $443.49 to $443.84. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 27, 2020 at each separate price. Read SEC document |
| February 27, 2020 Filed Feb 28, 2020 21:40 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 395 | $440.24 | $173,894.80 |
DisclosureSEC source: 0001708138-20-000017 · edgardoc.xml · nonDerivative · entry 8 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,810 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F7 · price: Represents volume-weighted average price of sales of 395 shares of Company stock on February 27, 2020 at prices ranging from $440.05 to $440.64. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 27, 2020 at each separate price. Read SEC document |
| February 27, 2020 Filed Feb 28, 2020 21:40 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 231 | $439.73 | $101,577.63 |
DisclosureSEC source: 0001708138-20-000017 · edgardoc.xml · nonDerivative · entry 7 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,205 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F6 · price: Represents volume-weighted average price of sales of 231 shares of Company stock on February 27, 2020 at prices ranging from $439.72 to $439.76. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 27, 2020 at each separate price. Read SEC document |
| February 27, 2020 Filed Feb 28, 2020 21:40 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 256 | $438.63 | $112,289.28 |
DisclosureSEC source: 0001708138-20-000017 · edgardoc.xml · nonDerivative · entry 6 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,436 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F5 · price: Represents volume-weighted average price of sales of 256 shares of Company stock on February 27, 2020 at prices ranging from $438.58 to $438.69. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 27, 2020 at each separate price. Read SEC document |
| February 27, 2020 Filed Feb 28, 2020 21:40 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 480 | $437.41 | $209,956.80 |
DisclosureSEC source: 0001708138-20-000017 · edgardoc.xml · nonDerivative · entry 5 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,692 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F4 · price: Represents volume-weighted average price of sales of 480 shares of Company stock on February 27, 2020 at prices ranging from $437.16 to $437.92. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 27, 2020 at each separate price. Read SEC document |
| February 27, 2020 Filed Feb 28, 2020 21:40 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 348 | $436.43 | $151,877.64 |
DisclosureSEC source: 0001708138-20-000017 · edgardoc.xml · nonDerivative · entry 4 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,172 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F3 · price: Represents volume-weighted average price of sales of 348 shares of Company stock on February 27, 2020 at prices ranging from $436.30 to $436.49. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 27, 2020 at each separate price. Read SEC document |
| February 27, 2020 Filed Feb 28, 2020 21:40 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 209 | $435.93 | $91,109.37 |
DisclosureSEC source: 0001708138-20-000017 · edgardoc.xml · nonDerivative · entry 3 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,520 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · price: Represents volume-weighted average price of sales of 209 shares of Company stock on February 27, 2020 at prices ranging from $435.90 to $435.96. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 27, 2020 at each separate price. Read SEC document |
| February 26, 2020 Filed Feb 28, 2020 21:40 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $52.03 | $0.00 |
DisclosureSEC source: 0001708138-20-000018 · edgardoc.xml · derivative · entry 4 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,079 Underlying: Common Stock · 25,000 shares Expires 2021-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · derivative.exercise_date: With respect to 75,000 underlying shares (of which 25,000 remain outstanding), the option became exercisable on December 31, 2014, based upon the satisfaction by the company of certain performance criteria during the period ended December 31, 2014. With respect to 48,079 underlying shares (of which 13,079 remain outstanding), the stock option award vested in four equal annual installments, commencing one year after the date of grant. F3 · balance_after: Form two of two Read SEC document |
| February 26, 2020 Filed Feb 28, 2020 21:40 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 14,651 | $451.89 | $6,620,640.39 |
DisclosureSEC source: 0001708138-20-000017 · edgardoc.xml · nonDerivative · entry 2 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,729 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| February 26, 2020 Filed Feb 28, 2020 21:40 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 25,000 | $52.03 | $1,300,750.00 |
DisclosureSEC source: 0001708138-20-000017 · edgardoc.xml · nonDerivative · entry 1 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,380 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| February 26, 2020 Filed Dec 11, 2020 21:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 750 | $0.00 | $0.00 |
DisclosureSEC source: 0001237899-20-000052 · edgardoc.xml · nonDerivative · entry 1 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,979 Read SEC document |
| February 13, 2020 Filed Feb 14, 2020 21:09 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 31 | $406.44 | $12,599.64 |
DisclosureSEC source: 0001237899-20-000008 · edgardoc.xml · nonDerivative · entry 7 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,380 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| February 13, 2020 Filed Feb 14, 2020 21:09 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,279 | $402.35 | $514,605.65 |
DisclosureSEC source: 0001237899-20-000008 · edgardoc.xml · nonDerivative · entry 6 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,411 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F5 · price: Represents volume-weighted average price of sales of 1,279 shares of Company stock on February 13, 2020 at prices ranging from $402.04 to $402.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 13, 2020 at each separate price. Read SEC document |
| February 13, 2020 Filed Feb 14, 2020 21:09 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2,058 | $401.46 | $826,204.68 |
DisclosureSEC source: 0001237899-20-000008 · edgardoc.xml · nonDerivative · entry 5 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,690 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F4 · price: Represents volume-weighted average price of sales of 2,058 shares of Company stock on February 13, 2020 at prices ranging from $401.11 to $401.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 13, 2020 at each separate price. Read SEC document |
| February 13, 2020 Filed Feb 14, 2020 21:09 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2,608 | $400.54 | $1,044,608.32 |
DisclosureSEC source: 0001237899-20-000008 · edgardoc.xml · nonDerivative · entry 4 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,748 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F3 · price: Represents volume-weighted average price of sales of 2,608 shares of Company stock on February 13, 2020 at prices ranging from $400.01 to $400.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 13, 2020 at each separate price. Read SEC document |
| February 13, 2020 Filed Feb 14, 2020 21:09 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 4,302 | $399.80 | $1,719,939.60 |
DisclosureSEC source: 0001237899-20-000008 · edgardoc.xml · nonDerivative · entry 3 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,356 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · price: Represents volume-weighted average price of sales of 4,302 shares of Company stock on February 13, 2020 at prices ranging from $399.04 to $399.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 13, 2020 at each separate price. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 21:09 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $52.03 | $0.00 |
DisclosureSEC source: 0001237899-20-000008 · edgardoc.xml · derivative · entry 11 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,079 Underlying: Common Stock · 25,000 shares Expires 2021-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F6 · derivative.exercise_date: With respect to 75,000 underlying shares (of which 50,000 remain outstanding), the option became exercisable on December 31, 2014, based upon the satisfaction by the company of certain performance criteria during the period ended December 31, 2014. With respect to 48,079 underlying shares (of which 13,079 remain outstanding), the stock option award vested in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 21:09 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 14,722 | $402.34 | $5,923,249.48 |
DisclosureSEC source: 0001237899-20-000008 · edgardoc.xml · nonDerivative · entry 2 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,658 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 21:09 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 25,000 | $52.03 | $1,300,750.00 |
DisclosureSEC source: 0001237899-20-000008 · edgardoc.xml · nonDerivative · entry 1 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,380 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| December 11, 2019 Filed Dec 13, 2019 21:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 24,500 | $0.00 Strike: $372.46 | $0.00 |
DisclosureSEC source: 0001237899-19-000029 · edgardoc.xml · derivative · entry 5 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,500 Underlying: Common Stock · 24,500 shares Expires 2029-12-11 F2 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| December 11, 2019 Filed Dec 13, 2019 21:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 2,625 | $0.00 | $0.00 |
DisclosureSEC source: 0001237899-19-000029 · edgardoc.xml · nonDerivative · entry 1 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,380 F1 · kind: Award of Restricted Stock under the Amended and Restated 2014 Long-Term Incentive Plan that vests 50% on December 11, 2021 and 50% on December 11, 2023. Read SEC document |
| November 26, 2019 Filed Nov 26, 2019 21:29 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 300 | $365.41 | $109,623.00 |
DisclosureSEC source: 0001237899-19-000025 · edgardoc.xml · nonDerivative · entry 5 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,455 F3 · price: Represents volume-weighted average price of sales of 300 shares of Company stock on November 26, 2019 at prices ranging from $365.26 to $365.55. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 26, 2019 at each separate price. Read SEC document |
| November 26, 2019 Filed Nov 26, 2019 21:29 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2,284 | $364.20 | $831,832.80 |
DisclosureSEC source: 0001237899-19-000025 · edgardoc.xml · nonDerivative · entry 4 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,755 F2 · price: Represents volume-weighted average price of sales of 2,284 shares of Company stock on November 26, 2019 at prices ranging from $364.00 to $364.40. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 26, 2019 at each separate price. Read SEC document |
| November 26, 2019 Filed Nov 26, 2019 21:29 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,422 | $363.58 | $517,010.76 |
DisclosureSEC source: 0001237899-19-000025 · edgardoc.xml · nonDerivative · entry 3 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,039 F1 · price: Represents volume-weighted average price of sales of 1,422 shares of Company stock on November 26, 2019 at prices ranging from $363.07 to $363.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 26, 2019 at each separate price. Read SEC document |
| November 25, 2019 Filed Nov 26, 2019 21:29 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $52.03 | $0.00 |
DisclosureSEC source: 0001237899-19-000025 · edgardoc.xml · derivative · entry 8 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,079 Underlying: Common Stock · 10,000 shares Expires 2021-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: With respect to 75,000 underlying shares, the option became exercisable on December 31, 2014, based upon the satisfaction by the company of certain performance criteria during the period ended December 31, 2014. With respect to 48,079 underlying shares (of which 13,079 remain outstanding), the stock option award vested in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| November 25, 2019 Filed Nov 26, 2019 21:29 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 5,994 | $362.75 | $2,174,323.50 |
DisclosureSEC source: 0001237899-19-000025 · edgardoc.xml · nonDerivative · entry 2 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,461 Read SEC document |
| November 25, 2019 Filed Nov 26, 2019 21:29 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 10,000 | $52.03 | $520,300.00 |
DisclosureSEC source: 0001237899-19-000025 · edgardoc.xml · nonDerivative · entry 1 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,455 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 08, 2019 Filed Nov 12, 2019 21:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 300 | $341.38 | $102,414.00 |
DisclosureSEC source: 0001708138-19-000010 · edgardoc.xml · nonDerivative · entry 11 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,455 F9 · price: Represents volume-weighted average price of sales of 300 shares of Company stock on November 8, 2019 at prices ranging from $341.09 to $341.72. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 8, 2019 at each separate price. Read SEC document |
| November 08, 2019 Filed Nov 12, 2019 21:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2,064 | $340.48 | $702,750.72 |
DisclosureSEC source: 0001708138-19-000010 · edgardoc.xml · nonDerivative · entry 10 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,755 F8 · price: Represents volume-weighted average price of sales of 2,064 shares of Company stock on November 8, 2019 at prices ranging from $340.00 to $340.84. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 8, 2019 at each separate price. Read SEC document |
| November 08, 2019 Filed Nov 12, 2019 21:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,100 | $339.53 | $373,483.00 |
DisclosureSEC source: 0001708138-19-000010 · edgardoc.xml · nonDerivative · entry 9 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,819 F7 · price: Represents volume-weighted average price of sales of 1,100 shares of Company stock on November 8, 2019 at prices ranging from $339.05 to $339.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 8, 2019 at each separate price. Read SEC document |
| November 08, 2019 Filed Nov 12, 2019 21:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,100 | $338.54 | $372,394.00 |
DisclosureSEC source: 0001708138-19-000010 · edgardoc.xml · nonDerivative · entry 8 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,919 F6 · price: Represents volume-weighted average price of sales of 1,100 shares of Company stock on November 8, 2019 at prices ranging from $338.10 to $338.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 8, 2019 at each separate price. Read SEC document |
| November 08, 2019 Filed Nov 12, 2019 21:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,500 | $337.41 | $506,115.00 |
DisclosureSEC source: 0001708138-19-000010 · edgardoc.xml · nonDerivative · entry 7 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,019 F5 · price: Represents volume-weighted average price of sales of 1,500 shares of Company stock on November 8, 2019 at prices ranging from $337.03 to $337.86. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 8, 2019 at each separate price. Read SEC document |
| November 08, 2019 Filed Nov 12, 2019 21:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 500 | $336.73 | $168,365.00 |
DisclosureSEC source: 0001708138-19-000010 · edgardoc.xml · nonDerivative · entry 6 STAHL NEIL · CIK 0001226689 · EVP Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,519 F4 · price: Represents volume-weighted average price of sales of 500 shares of Company stock on November 8, 2019 at prices ranging from $336.48 to $336.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 8, 2019 at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.